Home / Health / New Weight Loss Drug Dumps GLP-1 for Better Results
New Weight Loss Drug Dumps GLP-1 for Better Results
17 Apr
Summary
- Researchers are testing drugs targeting GIP and glucagon instead of GLP-1.
- Animal studies show this new approach matches or exceeds current drugs.
- The novel method may reduce side effects like nausea common with GLP-1s.
A new weight loss research strategy is questioning the essential role of GLP-1 drugs. Published on April 15, 2026, in Molecular Metabolism, the study explores targeting GIP and glucagon hormones instead. Early findings from mice, rats, and monkeys suggest this approach may achieve comparable or even superior weight loss.
This novel method, termed 'addition by subtraction,' entirely removes GLP-1 as a target. Researchers found that a triple-G drug, targeting GIP and glucagon, induced significant weight loss in mice engineered without GLP-1 receptors. Further experiments demonstrated that GIP and glucagon drugs working together may reduce appetite more effectively.
In animal trials, an experimental drug combining GIP and glucagon targets resulted in equal or greater weight loss than existing treatments. Beyond reducing food intake, it might also boost the body's energy expenditure. Notably, monkey studies indicated no distress at high doses of the new drug, unlike some existing weight loss medications.
While animal study results don't always predict human outcomes, this research offers a promising new perspective. Experts describe the findings as useful and impressive, highlighting a novel way to understand metabolic systems. However, potential heart benefits associated with GLP-1 drugs are not yet established for this new class.
